New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:47 EDTACT, PG, TEVATeva announces new organizational structure, senior leadership changes
Teva Pharmaceutical Industries announced a new organizational structure and related executive positions, which will become effective July 1. These changes are another key step in Teva's strategic direction to create a less complex, integrated company that can address the evolving needs of patients in the global markets in the most efficient, innovative and differentiated manner possible, the company said. Teva will be spearheaded by two commercial business units Global Specialty Medicines, established in April 2013, and the newly-formed Global Generic Medicines group. GGM will have full global responsibility for all existing generic markets. GGM will also be responsible for Teva's growing Over-the-Counter (OTC) business, led by Teva's joint venture with Procter and Gamble (PG). Teva announced that Sigurdur Olafsson has been appointed President and CEO of the newly formed Global Generic Medicines group and will assume this position on July 1, based in the U.S. Olafsson joins Teva from his previous role as President of Actavis Pharma (ACT). GSM, led by Dr. Rob Koremans, is responsible for Teva's global specialty medicines business and will continue to drive organic growth, with a strong pipeline of patient-centric solutions and new brands.
News For TEVA;PG;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 12, 2014
07:06 EDTTEVATeva upgraded to Buy from Neutral at Sterne Agee
Subscribe for More Information
December 11, 2014
19:06 EDTACTActavis confirms court ruling to require continued distribution of Namenda IR
Subscribe for More Information
10:13 EDTPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:39 EDTTEVATeva FY15 outlook appears strong, reasonable, says BMO Capital
Subscribe for More Information
07:50 EDTPGProcter & Gamble initiated with a Market Perform at Raymond James
Subscribe for More Information
07:24 EDTTEVATeva to host conference call
Subscribe for More Information
07:12 EDTTEVATeva sees FY15 Copaxone sales $3.5B-$3.7B
Sees FY15 Treanda sales $670M-$750M. Sees FY15 ProAir family sales $470M-$580M, Azilect sales $350M-$400M and Nuvigil sales $300M-$330M. Erez Vigodman, President & CEO of Teva, said, "Generics remain at the heart of our business, both as the cornerstone of the Company, but also as an area that has great impact on society. At the same time, we anticipate four specialty product approvals and five submissions in 2015 which we believe will improve treatment options for patients, and add value for all of our stakeholders." The company expects 2015 generic revenues in the United States to be $4.2B-$4.6B, $2.6B-$3.0B in Europe and $2.0B-$2.3B in its ROW markets. Results of its specialty segment are expected to be impacted by the introduction of two AB-rated generic competitors to Copaxone in the U.S. beginning in September 2015, which is a modeling assumption only, as well as by increased competition from oral products for the treatment of multiple sclerosis. In addition, the company is expecting to invest in a significant number of product launches and in its specialty pipeline. "All of these will result in lower profit and profitability, as we focus on generating growth over the next few years," Teva said.
07:08 EDTTEVATeva sees FY15 gross profit 59.5%-61.5%
Teva sees FY15 cash flow from operations $4.3B-$4.7B and free cash flow $3.5B-$3.7B.
07:07 EDTTEVATeva sees spending $1B-$1.2B on share buybacks in 2015
Subscribe for More Information
07:02 EDTTEVATeva sees FY15 EPS $5.00-$5.30, consensus $5.06
Sees FY15 revenue $19B-$19.4B, consensus $20.07B.
December 10, 2014
11:40 EDTACTActavis management to meet with Sterne Agee
Subscribe for More Information
09:33 EDTACTActavis launches generic version of Celebrex
Actavis (ACT) announced that it has launched a generic version of Celebrex 50 mg, 100 mg, 200 mg and 400 mg capsules, as part of a settlement agreement with Pfizer (PFE). Celebrex is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. For the 12-month period ending June 30, 2014, Celebrex had U.S. sales of approximately $2.4 billion, according to IMS Health data.
08:31 EDTTEVATeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
December 9, 2014
09:31 EDTACTZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
07:44 EDTTEVAAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:14 EDTACTAllergan price target raised to $245 from $210 at Citigroup
Subscribe for More Information
December 8, 2014
12:25 EDTACTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
11:30 EDTACT, TEVALeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
08:21 EDTTEVAMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
06:47 EDTTEVAArena says Teva files marketing authorization of Belviq in Israel
Arena Pharmaceuticals (ARNA) disclosed late Friday that Teva Pharmaceutical's (TEVA) local Israeli subsidiary, Abic Marketing Limited, has filed for marketing authorization of Belviq in Israel. In connection with the filing, Arena will receive a milestone payment of $250K.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use